Pediatric Obesity: Comprehensive Care and Practical Strategies for Today's Clinician Course at ObesityWeek® 2026

Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this live activity for a maximum of **9.5** *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity also offers **9.5** ABP Lifelong Learning and Self-Assessment MOC credits to those who meet threshold requirements.

ACCME Activity ID 203768762

Learning Objectives

1. Define best practices for managing pediatric obesity.
2. Accurately describe screening, treatment and referral in simulated scenarios for families impacted by the chronic disease of obesity.
3. Synthesize knowledge and skills to manage at least two complex pediatric obesity cases in a case simulation.
4. Demonstrate understanding of design for a clinical setting to support the delivery of interprofessional pediatric obesity care.

Commercial Support

This activity is supported in part by an educational grant from Novo Nordisk.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity - including faculty, planners, reviewers or others - are required to disclose all financial relationships with ineligible entities[1] (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all financial relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate financial relationships. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed.

Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker).

Panelists:

Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below. All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that "The content and/or presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased."

Speaker Disclosures:

First Name	Last Name	Degree	Disclosure
Sarah	Armstrong	MD	No Relevant Financial Relationships
Sarah	Barlow	MD, MPH	No Relevant Financial Relationships
E. Thomaseo	Burton	PhD, MPH	No Relevant Financial Relationships
Suzanne	Cuda	MD	No Relevant Financial Relationships

[1] An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compounds, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: https://accme.org/faq/what-accmes-definition-ineligible-company

Claudia	Fox	MD, MPH	Independent Contractor relationship with Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).
Sarah	Hampl	MD, FAAP	No Relevant Financial Relationships
Joan	Han	MD	Researcher relationship with Rhythm Pharmaceuticals (Pharmaceuticals).
Janet	Lydecker	PhD, FAED	No Relevant Financial Relationships
Mary	Savoye	MS, RD	No Relevant Financial Relationships
Webb	Smith	PhD	No Relevant Financial Relationships
Brooke	Sweeney	MD	Consultant relationship with Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Rhythm Pharmaceuticals (Pharmaceuticals). Researcher relationship with Rhythm Pharmaceuticals (Pharmaceuticals). Speaker relationship with Rhythm Pharmaceuticals (Pharmaceuticals).
Lisa	Watson	NP	No Relevant Financial Relationships

Planner Disclosures:

Name	Disclosure
Golden, Angela (DNP, FAANP, FOMA, FTOS)	Advisor relationship with Boehringer Ingelheim (Pharmaceuticals), Currax (Pharmaceuticals), Lilly (Pharmaceuticals), Epitomee (Pharmaceuticals), and Weight Watchers (Food). Consultant relationship with Novo Nordisk (Pharmaceuticals). Speaker relationship with Acella (Pharmaceuticals).
Kelly, Aaron (PhD, FTOS)	No Relevant Financial Relationships
Peterson, Eric D (EdM, CHCP)	No Relevant Financial Relationships
Skelton, Joseph (MD, MS, FTOS)	No Relevant Financial Relationships

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care. *This document was last updated October 29, 2026.*